1. Pink Sheet
  2. >>Geography
  3. >>Europe

Germany’s New Government Will Maintain Price Freeze And Slash Free Pricing Period

 
• By Francesca Bruce

Big changes are in store on the drug pricing front in Germany. Further reforms could depend on who is appointed health minister.

ice
Pharmaceutical Price Freeze To Remain In Place In Germany • Source: Alamy

The coalition partners that will form Germanys new government have reached an agreement that includes measures to contain health care costs by halving the period of free pricing for new pharmaceuticals and maintaining a controversial price freeze that critics say could deter investment. Industry experts warn that more reform is likely to come, potentially including measures that would affect orphan drugs and combination products.

Talks between the center-left Social Democrats (SPD), the Greens and the liberal pro-business Free Democrats (FDP) concluded last week. They had been ongoing since September when the SPD won something of a surprise victory in the federal elections

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.

EU Wants Industry To Define ‘Trade Secrets’ Under Health Data Sharing Regulation

 
• By Eliza Slawther

The European Health Data Space Regulation is deliberately “vague” when it comes to defining trade secrets because the EU wants the pharma industry to make recommendations on safeguarding intellectual property, a policy officer for the European Commission says.

Safety Review Prompts EMA to Suspend Ixchiq Chikungunya Vaccine For Seniors

 
• By Neena Brizmohun

The European Medicines Agency is investigating whether Valneva’s Ixchiq is safe to use in the elderly, following reports of 17 serious adverse events, including two cases resulting in death, in people aged 62 to 89 years who received the vaccine. This follows actions by US and French authorities last month regarding Ixchiq’s use in people over 65.

More from Geography